These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 32185696)

  • 41. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.
    Ling W; Chang L; Hillhouse M; Ang A; Striebel J; Jenkins J; Hernandez J; Olaer M; Mooney L; Reed S; Fukaya E; Kogachi S; Alicata D; Holmes N; Esagoff A
    Addiction; 2014 Sep; 109(9):1489-500. PubMed ID: 24825486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
    Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW
    Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions.
    Rose ME; Grant JE
    Ann Clin Psychiatry; 2008; 20(3):145-55. PubMed ID: 18633741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of protein kinase C in the neuropsychotoxicity induced by methamphetamine-like psychostimulants.
    Shin EJ; Dang DK; Hwang YG; Tran HQ; Sharma N; Jeong JH; Jang CG; Nah SY; Nabeshima T; Yoneda Y; Cadet JL; Kim HC
    Neurochem Int; 2019 Mar; 124():162-170. PubMed ID: 30654115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
    Tardelli VS; Bisaga A; Arcadepani FB; Gerra G; Levin FR; Fidalgo TM
    Psychopharmacology (Berl); 2020 Aug; 237(8):2233-2255. PubMed ID: 32601988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gender differences in methamphetamine use and responses: a review.
    Dluzen DE; Liu B
    Gend Med; 2008 Mar; 5(1):24-35. PubMed ID: 18420163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
    Marszalek-Grabska M; Gibula-Bruzda E; Jenda M; Gawel K; Kotlinska JH
    Brain Res; 2016 Jul; 1642():389-396. PubMed ID: 27085203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder.
    Chawarski MC; Hawk K; Edelman EJ; O'Connor P; Owens P; Martel S; Coupet E; Whiteside L; Tsui JI; Rothman R; Cowan E; Richardson L; Lyons MS; Fiellin DA; D'Onofrio G
    Ann Emerg Med; 2020 Dec; 76(6):782-787. PubMed ID: 32782084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
    Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
    J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topiramate in the treatment of substance-related disorders: a critical review of the literature.
    Shinn AK; Greenfield SF
    J Clin Psychiatry; 2010 May; 71(5):634-48. PubMed ID: 20361908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy of methamphetamine addiction: an update.
    Elkashef A; Vocci F; Hanson G; White J; Wickes W; Tiihonen J
    Subst Abus; 2008; 29(3):31-49. PubMed ID: 19042205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conditional Effects of Lifetime Alcohol Consumption on Methamphetamine-Associated Neurocognitive Performance.
    Saloner R; Paolillo EW; Umlauf A; Moore DJ; Heaton RK; Grant I; Cherner M;
    J Int Neuropsychol Soc; 2019 Sep; 25(8):787-799. PubMed ID: 31179969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial.
    Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K
    Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do prenatally methamphetamine-exposed adult male rats display general predisposition to drug abuse in the conditioned place preference test?
    Šlamberová R; Pometlová M; Schutová B; Hrubá L; Macúchová E; Nová E; Rokyta R
    Physiol Res; 2012; 61(Suppl 2):S129-38. PubMed ID: 23130898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle.
    Levi MS; Divine B; Hanig JP; Doerge DR; Vanlandingham MM; George NI; Twaddle NC; Bowyer JF
    Neurotoxicol Teratol; 2012 Mar; 34(2):253-62. PubMed ID: 22289608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.
    Chan B; Freeman M; Ayers C; Korthuis PT; Paynter R; Kondo K; Kansagara D
    Drug Alcohol Depend; 2020 Nov; 216():108193. PubMed ID: 32861136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health outcomes associated with methamphetamine use among young people: a systematic review.
    Marshall BD; Werb D
    Addiction; 2010 Jun; 105(6):991-1002. PubMed ID: 20659059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.